Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of Huanglian Jiedu Pills for Shi Re Huo Du syndrome
ChiCTR2300073160Phase 3Completed
- Sponsor
- First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
- Start
- Mar 2023
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute pharyngitis, aphthosis (RAS), gingivitis and 2 more comparing Huanglian Jiedu Pills with Placebo (2 arms). Primary endpoints: Treatment effective rate on Shi Re Huo Du syndrome after 5 days, Vital signs and 2 more. Started Mar 2023; status: completed.
02
Drugs
Huanglian Jiedu Decoction
03
Conditions
acute pharyngitisaphthosis (RAS)gingivitisconstipationdamp-heat toxin syndrome
Beyond the preview
Go deeper on ChiCTR2300073160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300073160.